Results 161 to 170 of about 10,208 (189)

The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection [PDF]

Journal of Clinical Investigation, 2012
It is estimated that one-third of the world's population is infected with Mycobacterium tuberculosis. Infection typically remains latent, but it can reactivate to cause clinical disease. The only vaccine, Mycobacterium bovis bacillus Calmette-Guérin (BCG), is largely ineffective, and ways to enhance its efficacy are being developed.
Philana Ling Lin, Jes Dietrich, Ed Klein
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

The Physical Stability of the Recombinant Tuberculosis Fusion Antigens H1 and H56

Journal of Pharmaceutical Sciences, 2013
The recombinant fusion proteins hybrid 1 [H1 (Ag85B-ESAT-6)] and hybrid 56 [H56 (Ag85B-ESAT-6-Rv2660c)] derived from Mycobacterium tuberculosis are promising antigens for subunit vaccines against tuberculosis. Both antigens are early batches of antigens to be enrolled in human clinical trials and it is therefore important to characterize their ...
Hamborg, Mette, Kramer, Ryan, Schanté, Carole E, Agger, Else Marie, Christensen, Dennis, Jorgensen, Lene, Foged, Camilla, Middaugh, C Russell   +7 more
openaire   +3 more sources

MPEC 2023-H56 : 2023 HU

2023
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire   +1 more source

A stochastic modeling study of H56 block in Daqingzijing oilfield

Arabian Journal of Geosciences, 2015
After years of water injection, the underground movement of oil and water in Daqingzijing oilfield is becoming more and more complex, and the distribution of reservoir parameters between wells and remaining oil is difficult to predict. The reservoir geological model of H56 block in Daqingzijing oilfield is established with the support of numerous data ...
Jianpeng Hou, Fang Ding, Weilu Li
openaire   +1 more source

Antiarrhythmic Properties of Stereoisomers of a Beta-adrenergic Blocking Agent (H56/28)

Anesthesiology, 1968
Cardiac arrhythmias were produced in the cat by inhalation of 1 per cent halopropane, 10 per cent CO2 and 89 per cent O2 and also by injection of epinephrine during inhalation of 1 per cent halopropane and 99 per cent O2. Dextro-H56/28, which has local anesthetic properties but only 1/40th the beta receptor blocking activity of the levo form of H56/28,
C O, Lord, R L, Katz, K E, Eakins
openaire   +2 more sources

H56 Driving performance of huntington’s disease gene carriers

Clinical care and clinical services, 2018
Background In patients with Huntington’s disease (HD), instrumental daily activities such as working and driving become affected at a relatively young age. For most patients, the decision to quit driving is difficult and affects their independence and social activities.
Milou Jacobs, Ellen P Hart, Yuri Mejia Miranda, Geert Jan Groeneveld, Joop MA van Gerven, Raymund AC Roos   +5 more
openaire   +1 more source

Immunogenicity of TB vaccine H56 in non-human primates (VAC4P.1113)

The Journal of Immunology, 2015
Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major global health problem. Several TB vaccine candidates are currently in various stages of development and clinical testing, including the protein subunit vaccine H56, from Statens Serum Institute (Copenhagen, Denmark).
Eileen Wong, Else Agger, Peter Andersen, JoAnne Flynn   +3 more
openaire   +1 more source

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

Vaccine, 2015
H56:IC31 is a candidate tuberculosis vaccine comprising a fusion protein of Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label phase I trial assessed the safety and immunogenicity of H56:IC31 in healthy adults without or with Mycobacterium tuberculosis (M.tb) infection.Low dose (15 μg H56 protein in 500 nmol IC31 ...
Angelique Kany Kany Luabeya, Michele D Tameris, Hennie D Geldenhuys   +2 more
exaly   +3 more sources

The TB vaccine H56+IC31 dose-response curve is peaked not saturating: Data generation for new mathematical modelling methods to inform vaccine dose decisions

Vaccine, 2016
In vaccine development, dose-response curves are commonly assumed to be saturating. Evidence from tuberculosis (TB) vaccine, H56+IC31 shows this may be incorrect. Mathematical modelling techniques may be useful in efficiently identifying the most immunogenic dose, but model calibration requires longitudinal data across multiple doses and time points.We
Sophie J Rhodes, Andrea Zelmer, Gwenan M Knight   +2 more
exaly   +4 more sources

H1- and H56- subunit vaccines against TB - an overview of the clinical development

European Respiratory Journal, 2014
Despite a very effective worldwide vaccination program, BCG vaccination has proven to be insufficient to provide protection against TB disease, and a better vaccine is urgently needed. Statens Serum Institut has developed two TB vaccine candidates, H1:IC and its improved successor H56:IC.
Morten Ruhwald, Else Marie Agger, Søren T. Hoff, Peter L. Andersen   +3 more
openaire   +1 more source